Angionorm

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Angionorm

Quick Facts

Property Description
Active Ingredient Metoprolol
Form Tablet (Oral formulation)
Pharmacological Class Cardioselective beta-Blocker
General Purpose Support of the cardiovascular system
Origin Synthetic Compound

What is Angionorm and its Pharmacological Identity?

Angionorm is the trade name for a synthetic prescription medicine whose active ingredient is Metoprolol, classified as a beta-Adrenergic Blocking Agent, or beta-blocker. It is a single-active-ingredient product designed for systemic action on the cardiovascular system.

The pharmacological identity of Metoprolol is defined by its cardioselectivity, meaning it primarily targets the beta1 receptors highly concentrated in the heart tissue. This distinction guides its role in medical practice, where the medicine is utilized to manage conditions requiring controlled regulation of cardiac activity. Its identity as a beta-blocker is clinically recognized for its reliable action in cardiovascular support.

Composition, Salt Forms, and Delivery Type

Angionorm is supplied as an oral formulation in the form of a tablet, intended to be taken by mouth. The active ingredient, Metoprolol, is manufactured in two primary salt types: Metoprolol Tartrate and Metoprolol Succinate.

These two salt types determine the drug's release mechanism, which is a crucial factor in patient care. The tartrate form often provides immediate release, while the succinate salt is typically engineered as an extended-release formulation, designed to provide a steady effect over a prolonged period. This difference in release profile ensures the medicine can offer continuous, stable cardiac support.

General Purpose and Core Physiological Benefit

The general purpose of Angionorm is to reduce the overall effort and strain experienced by the heart muscle. By selectively blocking stress hormones' effects on the heart, the medicine initiates a controlled reduction in the heart rate and lessens the force of its contractions.

This physiological action translates into a core benefit: a decreased demand for oxygen and energy by the cardiac muscle. This promotes a more stable and energy-efficient status for the cardiovascular system by maintaining controlled function.

Regulatory References

  1. MedlinePlus

What side effects are possible with Angionorm?

Possible Side Effects and Safety Information

The safety profile of Angionorm (Metoprolol) is established by regulatory bodies, detailing the categories, frequency, and systems affected by potential adverse reactions. The most common effects documented include tiredness/fatigue, dizziness, headache, and a potentially slow heart rate (bradycardia), generally falling into the Common classification (occurring in up to 1 in 10 patients).


Adverse Reactions by System-Organ Class

The official labeling groups adverse reactions primarily within the Cardiovascular, Nervous System, and Gastrointestinal disorders. Uncommon or rare effects may involve psychiatric disorders (e.g., depression, nightmares) or vascular disorders (e.g., cold extremities, Hypotension).

Serious Safety Considerations and Restrictions

Specific serious risks are officially documented. The medicine is Contraindicated in patients with certain severe conditions, including Cardiogenic Shock, Severe Bradycardia, or Decompensated Heart Failure. A critical safety pattern relates to Abrupt Cessation; regulatory documents warn that abruptly stopping therapy may exacerbate angina pectoris or precipitate a myocardial infarction, necessitating a gradual reduction in dose over one to two weeks.

Population-Specific Notes

Safety notes specify required caution for certain patient populations. Individuals with Hepatic Impairment may require close monitoring due to altered drug clearance. In patients with Bronchospastic Disease, the lowest effective dose should be used due to Metoprolol's relative but incomplete cardioselectivity. Furthermore, the label notes that the medication may mask some signs of hypoglycemia in diabetic patients.

Overdose and Emergency Response

Overdose and when to seek help

The information below summarizes the officially documented descriptions of overdose for Angionorm (Metoprolol), based strictly on government regulatory sources.


Documented Overdose Manifestations

Overdose may present with serious physiological signs rooted in the drug's action on the cardiovascular system. Documented manifestations include severe bradycardia (abnormally slow heart rate), hypotension (low blood pressure), and conduction disorders like atrioventricular (AV) block. Other signs include heart failure, respiratory effects such as bronchospasm and hypoxia, and effects on the central nervous system, including impairment of consciousness that may progress to coma.


Life-Threatening Outcomes and Emergency Actions

The regulatory labeling states that overdose can lead to severe outcomes such as cardiogenic shock and significant hemodynamic instability. Patients with existing cardiovascular conditions like myocardial infarction or heart failure are noted as being particularly prone to this instability.

Immediate medical attention must be sought for any suspected overdose. Treatment is officially described as symptomatic and supportive, often requiring treatment in an intensive care setting. Supportive measures may include the administration of agents like Atropine, vasopressors (such as Dopamine or Norepinephrine), and Glucagon to manage the most severe effects.

Therapeutic Uses of Angionorm

What Angionorm Treats: Main Uses and Benefits

Angionorm is commonly used across major cardiovascular domains and is applied in situations involving certain distressing symptoms. It is applied in contexts marked by increased discomfort or tension related to the cardiovascular system. The medication is considered relevant for easing symptoms related to: systemic hypertension (high blood pressure), Angina Pectoris (chest discomfort), Arrhythmias (irregular heart rhythms), and to support patients in the long-term management following a myocardial infarction (heart attack) and specific types of Chronic Heart Failure.

It also may be part of symptomatic management for recurrent Migraine headaches. The medicine is applied in scenarios where additional management of discomfort is required, helping to address symptom clusters that may become intense or disruptive. As a result, the therapy provides supportive relief that may help patients cope more steadily with symptom fluctuations and can assist with maintaining functional stability.


Quick Fact: Relief for Cardiac and Vascular Strain

Angionorm supports general well-being by contributing to easing the overall symptom load related to systemic imbalance.


“The primary benefit of Angionorm's therapeutic area is to assist in easing the impact of symptoms on routine activities and general comfort.”

Regulatory References

  1. NIH StatPearls Overview of Metoprolol Uses

Eligibility and Restrictions for Use

Eligibility for Angionorm (Metoprolol): Official Regulatory Status

Eligibility to use Angionorm is strictly defined by regulatory authorities based on pre-existing conditions and demographic factors, establishing clear limits on its use.

Absolute Contraindications

Use is contraindicated (absolutely prohibited) in patients with specific, severe conditions, including cardiogenic shock, decompensated heart failure, severe bradycardia (very slow heart rate), and certain types of high-grade heart block (second or third-degree heart block, unless a functioning pacemaker is present). Patients with severe hypotension (very low blood pressure) must also not use this medicine.


Age- and Condition-Based Restrictions

Population Group Regulatory Status
Pediatric (Under 6 years) Safety and efficacy are not established; use is not recommended.
Pediatric (6 years and older) Approved for hypertension only (typically extended-release formulation).
Hepatic Impairment Use with caution; potential dose reduction required in severe cases.
Bronchospastic Disease Use is generally not recommended but may be considered cautiously at the lowest dose.
Pregnancy Not recommended unless therapeutic benefit outweighs potential fetal risk.

Adults with approved cardiovascular conditions, such as hypertension and stable heart failure, are generally eligible. Caution is advised for older adults due to the increased possibility of age-related organ impairment. These restrictions ensure the medicine is only used by populations for whom its safety and efficacy profile has been officially documented.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Angionorm (Metoprolol) is determined by its CYP2D6 metabolic pathway and potential for additive pharmacodynamic effects, as documented in government regulatory labeling.

Documented Interaction Patterns

Classification Interacting Entity Official Regulatory Statement
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs) Prohibited due to the risk of additive hypotensive and bradycardic effects.
Metabolic Pathway Strong CYP2D6 Inhibitors (e.g., Paroxetine, Fluoxetine) Increases metoprolol plasma concentration several-fold, diminishing the medicine’s cardioselectivity.
Additive Effect Calcium Channel Blockers (Verapamil/Diltiazem types) Increases the risk of severe bradycardia and hypotension.
Timing-Based Rule Clonidine Withdrawal Metoprolol should be withdrawn several days before the gradual withdrawal of Clonidine to prevent exacerbated rebound hypertension.
Absorption Modifier Food (Immediate-Release formulation) Increases the oral absorption of the medicine.

These statements are based on the FDA Prescribing Information and the European Summary of Product Characteristics (SmPC), defining the necessity for caution with substances that affect cardiac rhythm or systemic exposure. For instance, CYP2D6 Poor Metabolizers exhibit markedly higher exposure to metoprolol compared to normal metabolizers. Additionally, substances like Aluminum Hydroxide may decrease metoprolol levels by inhibiting gastrointestinal absorption, which requires separation of administration.

Mechanism of Action

Angionorm, whose active component is Metoprolol, functions via a specific mechanism involving the modulation of sympathetic nervous system signaling at the receptor level.

Selective beta1-Receptor Blockade in Cardiac Tissue

The primary action of Angionorm is centered on its role as a competitive antagonist against the beta1-adrenergic receptors found in the heart's conduction and muscle tissue. By preventing Norepinephrine and Epinephrine from binding, the drug effectively dampens the cAMP signaling cascade inside the cardiac cells. This molecular action directly produces a slowing of the heart rate (negative chronotropic effect) and a reduction in the force of heart contraction (negative inotropic effect), resulting in a reduction of the heart muscle's demand for oxygen and energy.

Modulation of Systemic Neurohormonal Pathways

The drug's mechanism also extends beyond the heart to modulate systemic regulatory pathways. Specifically, Metoprolol blocks the beta1-receptors located in the kidney's juxtaglomerular apparatus, leading to a direct suppression of Renin release. Renin is a key initiator of the Renin-Angiotensin-Aldosterone System (RAAS), which leads to the modulation of systemic neurohormonal pathways and vascular tone.

Contextual Mechanism Limitation (Dose-Selectivity)

It is mechanistically important to note that the drug's beta1-selectivity is relative and dose-dependent. At sufficiently high plasma concentrations, the drug may also begin to engage the beta2-adrenergic receptors located in the bronchial and vascular smooth muscle. This relationship demonstrates that selectivity for beta1 receptors over beta2 receptors is concentration-dependent, diminishing when plasma levels exceed the selective threshold.

Dosage and Administration Information

Administration and Dosage Guidelines

Angionorm is a drug that should only be used as directed by a healthcare professional. The specific dosage and duration of treatment are determined by your doctor, based on your medical condition and individual response to therapy. Patients are advised to strictly adhere to the prescribed regimen and not to alter the dose or stop taking the medication without prior consultation.

General Administration

Angionorm is typically administered orally. The tablets should be swallowed whole with a glass of water and are generally recommended to be taken with food, or immediately after a meal, to minimize potential gastrointestinal discomfort. Do not crush, break, or chew the tablets unless explicitly instructed by your physician or pharmacist, as this may affect the drug's release mechanism and efficacy.

Dosing for Specific Indications

The dosage for Angionorm may vary widely depending on the treated condition, which often involves chronic vascular disorders, including those associated with disturbed microcirculation and elevated platelet aggregation. A common starting dosage for adult patients may be one tablet taken orally two or three times per day, but this must be confirmed and customized by a healthcare provider. Patients who miss a dose should take it as soon as they remember, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped to avoid taking a double dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Angionorm

This section summarizes the official research evidence for Angionorm (Metoprolol), focusing on the types of studies conducted, the outcomes researchers monitored, and areas where data remain limited, according to authoritative governmental and scientific sources.


Research Evidence for Major Cardiovascular Uses

Research for Angionorm has focused on its use in Chronic Heart Failure and Post-Myocardial Infarction management through large Randomized Controlled Trials (RCTs). The research examined all-cause mortality and the frequency of hospitalization. Studies also reported measurements of Left Ventricular Ejection Fraction (LVEF) and functional status. Findings regarding all-cause mortality have been described primarily with the extended-release succinate salt formulation.

A key study limitation is that some research observed that very early intravenous administration was associated with different findings in the highest-risk heart attack patient groups. Furthermore, research is ongoing regarding the necessity of continued use in patients whose heart function is determined to be preserved after the initial event.


Research on Physiological and Symptomatic Monitoring

Angionorm was evaluated in studies focused on Systemic Hypertension and Angina Pectoris. Studies monitored physiological strain, primarily focusing on short-term and sustained measurements of systolic and diastolic blood pressure readings. For Angina Pectoris, studies measured the frequency and intensity of outcomes related to physical discomfort.

Data show patterns related to the monitored blood pressure measurements and physiological stabilization that research explored in both conditions. The research also examined outcomes related to acute events like stroke or heart attack over follow-up durations spanning several years.


Evidence Gaps and Studies in Specific Groups

The evidence base is smaller and certainty remains low in certain secondary applications, such as the use for migraine prevention, compared to primary cardiovascular studies. Angionorm was evaluated in studies for conditions like hypertension in children and adolescents, but these studies typically use smaller sample sizes and follow-up durations were limited.

Evidence quality varies across studies, and comparative evidence is lacking in some areas against newer drug classes. The evidence base for rare or specific comorbidities remains insufficient, and research does not determine whether an individual will respond similarly to the reported group patterns.

Key Studies & References

  1. NIH StatPearls: Metoprolol (Overview of Uses)
  2. MedlinePlus: Metoprolol (Salt Forms and Release Mechanisms)
  3. Evidence-based guidelines for migraine prevention: Assessment of efficacy and review of adverse events

Frequently Asked Questions (FAQ)

Common questions about Angionorm (FAQ)

Q: If I miss a dose of Angionorm, what generally happens?

A: Official regulatory instructions focus on managing a missed dose according to the standard administration rule to help avoid taking a double dose. Official information does not typically describe the direct feeling or consequence (what happens) of missing a single dose.

Q: Does Angionorm cause weight gain or loss?

A: Weight gain has been very rarely reported in studies documented by regulatory sources, but the official data does not establish a clear cause-and-effect link to the medicine. Weight loss, conversely, was generally not reported in the available official data for this medicine.

Q: Are headaches a common side effect reported with Angionorm?

A: Yes, regulatory documents list headaches among the common side effects associated with this medicine. This is described as occurring in up to 1 in 10 patients in clinical studies.

Q: Can Angionorm affect sleep patterns?

A: Official documentation reports that sleep patterns can be affected. Side effects such as nightmares, insomnia (difficulty sleeping), and general sleep disturbances have been reported, typically categorized as uncommon or rare in official product information.

Q: Does Angionorm have a specific warning about grapefruit juice?

A: Regulatory documents do not typically contain a specific warning about an interaction with grapefruit juice for this medicine. Patients are advised to discuss their full diet, including foods and drinks, with a healthcare professional.

Q: Are there any specific times of day Angionorm is usually taken?

A: Official product information often recommends that the medicine be taken consistently with food or immediately after a meal to support consistent absorption. Beyond consistent timing with food, regulatory documents do not specify a fixed time of day, such as morning or evening.

Q: Is it okay to drive or operate machinery while on Angionorm?

A: Official labeling advises patients to use caution and determine how the medicine affects them personally before attempting to drive or operate machinery. This is due to the potential for side effects like dizziness, confusion, or fatigue.

Q: How quickly should someone expect to feel different after starting Angionorm?

A: The physiological effect of the medicine, such as slowing the heart rate and lowering blood pressure, begins relatively quickly after administration. However, the time required to achieve the full, intended therapeutic benefit is determined individually and based on the underlying condition.

Q: Is it normal to feel a bit tired when first taking Angionorm?

A: Yes, tiredness and fatigue are noted in regulatory documents as among the most common side effects reported. The intensity of these initial effects may lessen as the body adjusts to the medicine.

Q: Does Angionorm interact with common pain relievers like ibuprofen?

A: Regulatory documents note that Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen, may reduce the blood pressure-lowering effect of Angionorm. It is generally advised to discuss all over-the-counter pain relievers with a healthcare professional.

Q: Can you take Angionorm with vitamins or dietary supplements?

A: Official regulatory information advises that individuals discuss all supplements and vitamins with their healthcare provider. Certain mineral supplements may potentially decrease the body's absorption of the medicine.

Q: What types of food interactions are listed for Angionorm?

A: The main interaction documented in regulatory information is that food increases the oral absorption of the medicine. This is why consistent administration with or immediately after a meal is often recommended to support consistent levels.

Q: Is Angionorm suitable for people who have kidney issues?

A: The active ingredient in Angionorm is primarily processed by the liver, not the kidneys. Because of this, regulatory information generally states that a routine dose adjustment is not required for renal impairment.

Q: Is Angionorm considered a long-term treatment?

A: Yes. According to official guidelines, this medicine is indicated for the long-term treatment of chronic cardiovascular conditions, such as hypertension and angina pectoris.

Q: What happens if someone stops taking Angionorm suddenly?

A: Official regulatory documents carry specific warnings against abrupt cessation of therapy. Suddenly stopping the medicine may exacerbate angina pectoris (chest pain) or precipitate a myocardial infarction, necessitating a gradual dose reduction, as directed by a healthcare professional.

Q: Does Angionorm require regular blood tests?

A: Official documentation advises that monitoring of certain parameters may be required by a healthcare provider while on treatment. This monitoring can include assessments of liver, kidney, and thyroid function, and blood sugar, particularly for patients with diabetes.

Q: Are there any specific lifestyle changes recommended when taking Angionorm?

A: Official patient materials often emphasize that the medicine is part of a complete program. This comprehensive approach frequently includes supportive measures like dietary management (such as low fat/salt), maintaining a healthy weight, and exercise.

Q: Is Angionorm used off-label by some doctors?

A: Official regulatory documents define only the approved uses for the medicine. However, the active ingredient has been the subject of research for unapproved areas like migraine prevention and certain types of tachyarrhythmias.

Q: Is Angionorm a diuretic?

A: No. Angionorm is officially classified as a cardioselective beta-blocker, meaning it targets specific receptors in the heart. It is not classified as a diuretic, which is also known as a water pill.

Q: Are there reports of Angionorm affecting mood or anxiety?

A: Yes, official regulatory documents list effects related to mental health. Depression is listed as a common side effect, and anxiety and nervousness are listed among the rare side effects in the psychiatric disorder category.

Q: Can Angionorm cause stomach problems like nausea or diarrhea?

A: Yes. Regulatory documents list several gastrointestinal issues as common side effects reported in clinical studies. These include nausea, vomiting, diarrhea, constipation, and stomach pain.

Q: Does Angionorm interact with medicines for diabetes?

A: Regulatory documents contain a specific warning that the medicine may mask symptoms of low blood sugar (hypoglycemia). It may mask the fast heartbeat response typically associated with low blood sugar in diabetic patients.

Q: Is Angionorm a medicine that affects blood clotting?

A: No. Official information indicates that Angionorm is not a blood thinner. Its primary action is focused on the heart and blood vessels, not directly on the blood clotting process.

Q: What is the maximum duration of use mentioned in official guidelines for Angionorm?

A: The medicine is officially indicated for the long-term treatment of chronic conditions. Regulatory guidelines therefore do not establish a fixed maximum duration for appropriate use.

Q: Is it true that Angionorm can cause swelling in the ankles?

A: Yes. Official regulatory documents report swelling of the feet, ankles, or lower legs (peripheral edema) as a potential side effect. This is sometimes categorized as a common or uncommon finding.

Q: Why do some people refer to Angionorm as a 'heart pill'?

A: This colloquial term is likely used because the medicine is officially classified as a cardioselective beta-blocker. This means it is specifically designed to primarily target the heart to help control its rate and force of contraction.

Q: What does 'Angionorm is indicated for...' mean in simple terms?

A: The term 'indicated for' simply means the specific medical conditions or uses for which the medicine has received official regulatory approval. It defines the officially recognized purposes of the medicine.

Q: Are there any patient registries or observational studies related to Angionorm?

A: Yes. Beyond the primary randomized controlled trials (RCTs) used for initial approval, the drug's use is commonly followed by observational studies and the establishment of registries to track long-term safety and effectiveness patterns.

Q: What should a patient do if they develop a rash while taking Angionorm?

A: Official regulatory documents list skin rash or itching as a potential side effect. Official documents reference the need for medical attention for more serious signs of allergic reaction, such as swelling or difficulty breathing.

Q: Does Angionorm require special monitoring if you have low blood pressure?

A: Yes. Low blood pressure (hypotension) is a known potential effect of the medicine. The official label describes the need for monitoring blood pressure, especially when therapy is initiated.

How should Angionorm be stored and disposed of?

How to Store and Dispose of Angionorm (Metoprolol)

Angionorm must be stored strictly according to regulatory labeling to maintain its efficacy and safety profile.


Storage Requirements

Item Regulatory Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Protect from light and moisture. Do not freeze.
Child Safety Keep out of the sight and reach of children.
Packaging Store in the tightly closed, original package.

Disposal Instructions

Expired or unused Angionorm must not be thrown away via household waste or wastewater. Disposal should be managed by returning the medicine to a pharmacist or a designated collection point, ensuring compliance with local requirements and environmental protection mandates.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Angionorm found in:

A-Z Index: